•
Feb 29, 2024

Walgreens Q2 2024 Earnings Report

Walgreens reported a mixed second quarter with sales growth offset by a net loss due to impairment charges, while adjusted EPS increased slightly.

Key Takeaways

Walgreens Boots Alliance (WBA) announced its fiscal 2024 second quarter results, revealing a 6.3% increase in sales to $37.1 billion, but a net loss of $5.9 billion due to a $5.8 billion after-tax non-cash impairment charge related to VillageMD goodwill. Adjusted EPS increased by 3.4% to $1.20. The company narrowed its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35.

Sales increased 6.3% year-over-year to $37.1 billion, or 5.7% on a constant currency basis.

Loss per share was $6.85, compared to earnings per share of $0.81 in the year-ago quarter, impacted by a $5.8 billion after-tax non-cash impairment charge.

Adjusted EPS increased 3.4% to $1.20, or 2.8% on a constant currency basis.

Fiscal 2024 adjusted EPS guidance narrowed to $3.20 to $3.35.

Total Revenue
$37.1B
Previous year: $34.9B
+6.3%
EPS
$1.2
Previous year: $1.16
+3.4%
Prescriptions Filled
305.3M
Gross Profit
$7.04B
Previous year: $7.06B
-0.2%
Cash and Equivalents
$668M
Previous year: $1.09B
-38.6%
Free Cash Flow
-$610M
Previous year: $248M
-346.0%
Total Assets
$84.2B
Previous year: $100B
-16.2%

Walgreens

Walgreens

Walgreens Revenue by Segment

Forward Guidance

Walgreens Boots Alliance narrowed its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35, reflecting challenges in the retail environment, the early wind-down of the sale-leaseback program, and lower earnings due to Cencora share sales, offset by pharmacy services execution and a lower adjusted effective tax rate.

Positive Outlook

  • Execution in pharmacy services is expected to offset some challenges.
  • A lower adjusted effective tax rate is anticipated.
  • U.S. Healthcare adjusted EBITDA is maintained to be breakeven at the midpoint of the guidance range.
  • Company confident in goal of achieving $1 billion in cost savings this year.
  • Team members are powering progress as we map growth opportunities.

Challenges Ahead

  • Challenging retail environment in the U.S. is impacting performance.
  • Early wind-down of the sale-leaseback program is creating headwinds.
  • Lower earnings are expected due to Cencora share sales.
  • Operating cash flow was negatively impacted by payments related to legal matters.
  • Softer U.S. retail performance and lower sale-leaseback gains, partly offset by improved profitability in the U.S. Healthcare segment.

Revenue & Expenses

Visualization of income flow from segment revenue to net income